|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 725.72 USD | -4.21% |
|
-9.00% | -5.99% |
| Jan. 17 | S&P 500 Logs 2.9% Weekly Gain on Easing Inflationary Pressures, Strong Bank Earnings | MT |
| Jan. 17 | What Wegovy's inclusion in Medicare price negotiation means for patients, company | RE |
| Capitalization | 653B 628B 593B 531B 936B 56,335B 1,044B 7,208B 2,671B 23,242B 2,451B 2,400B 101,725B | P/E ratio 2024 * |
57.8x | P/E ratio 2025 * | 33.6x |
|---|---|---|---|---|---|
| Enterprise value | 676B 650B 613B 549B 967B 58,236B 1,079B 7,451B 2,761B 24,026B 2,534B 2,481B 105,157B | EV / Sales 2024 * |
14.9x | EV / Sales 2025 * | 11.5x |
| Free-Float |
99.81% | Yield 2024 * |
0.72% | Yield 2025 * | 0.83% |
More valuation ratios
* Estimated data
More news
Last Transcript: Eli Lilly and Company
More recommendations
More press releases
| 1 day | -4.21% | ||
| 1 week | -9.00% | ||
| Current month | -5.99% | ||
| 1 month | -5.48% | ||
| 3 months | -20.94% | ||
| 6 months | -15.36% | ||
| Current year | -5.99% |
1 week
725.01
765.51
1 month
725.01805.34
Current year
725.01805.34
1 year
614.82972.53
3 years
231.87972.53
5 years
117.06972.53
10 years
64.18972.53
| Director | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 57 | 2016-12-31 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 48 | 2024-09-08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 64 | 2004-12-31 |
Ralph Alvarez
BRD | Director/Board Member | 68 | 2009-03-31 |
| Director/Board Member | 53 | 2011-12-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 30 M€ | +1.14% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -4.21% | -9.00% | +15.45% | +198.49% | 653B | ||
| -0.50% | +1.77% | -9.06% | -11.03% | 354B | ||
| -4.22% | -10.08% | -24.73% | +73.23% | 341B | ||
| -1.23% | -2.93% | +4.12% | +28.96% | 303B | ||
| -2.76% | -3.03% | -17.64% | +21.26% | 248B | ||
| +0.57% | +0.76% | +9.34% | -26.90% | 236B | ||
| -1.32% | -0.26% | +2.72% | +22.08% | 206B | ||
| -0.10% | -1.72% | -4.87% | +9.63% | 197B | ||
| -0.72% | -1.87% | -7.00% | -51.34% | 149B | ||
| +0.99% | +0.71% | -11.60% | +18.88% | 146B | ||
| Average | -1.35% | -1.83% | -4.33% | +28.33% | 283.38B | |
| Weighted average by Cap. | -1.96% | -3.21% | -1.98% | +56.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 45.27B 43.53B 41.1B 36.8B 64.82B 3,903B 72.29B 499B 185B 1,610B 170B 166B 7,047B | 58.33B 56.09B 52.95B 47.42B 83.52B 5,028B 93.14B 643B 238B 2,074B 219B 214B 9,080B |
| Net income | 11.12B 10.7B 10.1B 9.04B 15.93B 959B 17.76B 123B 45.47B 396B 41.72B 40.86B 1,732B | 19.41B 18.67B 17.62B 15.78B 27.8B 1,674B 31B 214B 79.35B 690B 72.81B 71.3B 3,022B |
| Net Debt | 22.05B 21.2B 20.02B 17.93B 31.57B 1,901B 35.21B 243B 90.12B 784B 82.69B 80.99B 3,432B | 16.55B 15.92B 15.03B 13.46B 23.7B 1,427B 26.44B 183B 67.67B 589B 62.09B 60.81B 2,577B |
More financial data
* Estimated data
Employees
43,000
Sector
Pharmaceuticals
Calendar
2025-02-06
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-17 | 725.72 $ | -4.21% | 5,560,101 |
| 25-01-16 | 757.60 $ | +1.45% | 3,070,254 |
| 25-01-15 | 746.74 $ | +0.25% | 5,736,908 |
| 25-01-14 | 744.91 $ | -6.59% | 10,372,975 |
Delayed Quote Nyse, January 17, 2025 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
725.72USD
Average target price
977.47USD
Spread / Average Target
+34.69%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
